Back to results
US 2020/0046682 A1Published application
Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
AssigneesEpicentRx, Inc., Northrop Grumman Innovation Systems, Inc.
InventorsMark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
Life of this patent
Estimating the term…
Abstract
The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
Claims10
A compound of structural Formula (I):
- or salts, solvates or hydrates thereof wherein:
- R1, R2, R3 and R4 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;
- each R5 and R6 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;
- o is 0, 1, 2, 3 or 4;
- R7 is substituted alkyl, substituted arylalkyl, substituted heteroalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl;
- provided that at least one of R1, R2, R3, R4, R5 and R6 are nitro.
3 more elements
-16. (canceled)
(canceled)
Dependencies are inferred from the claim text.